The tweet was deleted by the author.
But we saved everything 🙂.
Biomea Fusion announced that three abstracts have been accepted for poster presentation at the American Diabetes Association 86th Scientific Sessions scheduled for June 5–8 in New Orleans.
According to the company, these presentations will deliver new data on their investigational therapy icovamenib, covering applications in both type 1 and type 2 diabetes. This move underscores Biomea Fusion intent to advance innovation in diabetes research by sharing early-stage findings with the wider medical and scientific community.
Biomea Fusion has previously reported that diabetes remains poorly controlled in many patients, highlighting unmet needs in current treatment options (link). The company recently began enrolling participants in the COVALENT-212 clinical trial to study icovamenib in type 2 diabetes (link). These efforts come as Biomea Fusion continues to advance clinical research for new diabetes therapies.